Home

Johnson & Johnson (JNJ)

190.40
-2.07 (-1.08%)
NYSE · Last Trade: Oct 26th, 6:18 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close192.47
Open192.20
Bid190.40
Ask190.55
Day's Range189.42 - 192.31
52 Week Range140.68 - 194.48
Volume6,903,411
Market Cap500.50B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield5.200 (2.73%)
1 Month Average Volume8,715,516

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

Market Minute: Dow Hits Record Highs, S&P 500 Surges Past 6,800 as Inflation Cools
October 24, 2025 – The U.S. stock market experienced an electrifying day of trading, with major indices soaring to unprecedented levels. The Dow Jones Industrial Average (DJIA) shattered previous records, closing above 47,000 for the first time, while the S&P 500 (SPX) surged past the 6,800 mark.
Via MarketMinute · October 24, 2025
Economic Data Blackout: Government Shutdown Casts Shadow Over Market Clarity
Washington D.C., October 24, 2025 – As the U.S. federal government enters its 24th day of an ongoing shutdown, a critical "economic data blackout" is increasingly clouding the financial landscape. The prolonged funding lapse, which commenced on October 1st, has already led to significant delays in the release of
Via MarketMinute · October 24, 2025
Kenvue Stock Climbs Premarket, Day After Record Slide On UK Lawsuit: Retail Bulls Remain Unshakenstocktwits.com
Via Stocktwits · October 17, 2025
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrepbenzinga.com
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.
Via Benzinga · October 24, 2025
IMF Sounds Alarm: 'Shifting Ground Beneath the Calm' Threatens Global Financial Stability
Washington D.C. – October 23, 2025 – The International Monetary Fund (IMF) has today released its Global Financial Stability Report (GFSR) for October 2025, titled "Shifting Ground beneath the Calm," delivering a stark warning that beneath the surface of seemingly tranquil global financial markets, significant vulnerabilities are festering. The report highlights
Via MarketMinute · October 23, 2025
Flash PMI: The Early Warning System Guiding the Federal Reserve's Hand
Flash Purchasing Managers' Index (PMI) data, a critical economic bellwether, continues to command significant attention from financial markets and policymakers alike. Released typically a week or two ahead of final PMI figures and other major government economic reports, this forward-looking indicator provides an invaluable, real-time snapshot of the health and
Via MarketMinute · October 23, 2025
Integer Holdings (ITGR) Shares Plunge 31.4% as Slower New Product Adoption and Revised Guidance Rock Investor Confidence
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
Via MarketMinute · October 23, 2025
Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a Fireside Chat at 10:40 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · October 22, 2025
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
Via MarketMinute · October 22, 2025
Intuitive Surgical Soars on Stellar Q3 2025 Earnings, Driven by Da Vinci 5 Adoption
Intuitive Surgical (NASDAQ: ISRG), the global leader in robotic-assisted surgery, announced a robust third quarter for 2025, sending its stock soaring as investors cheered impressive financial results and strong adoption of its latest da Vinci 5 surgical system. The company's report, released on October 21, 2025, showcased significant revenue and
Via MarketMinute · October 22, 2025
Boston Scientific Soars: Q3 2025 Earnings Beat Ignites Medical Device Market
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
Via MarketMinute · October 22, 2025
Ominous Echoes: U.S. Job Growth Stalls to 2009 Levels, Signaling Deep Labor Market Fragility
WASHINGTON D.C. – October 21, 2025 – A concerning report from investment giant Vanguard has cast a long shadow over the U.S. labor market, revealing that job growth plummeted to a mere 0.1% for seven of the first nine months of 2025. This alarming deceleration, with September 2025 hitting
Via MarketMinute · October 21, 2025
Johnson & Johnson Draws Long-Term Buyers as Markets Turn Cautiousfool.com
Johnson & Johnson Draws Long-Term Buyers as Markets Turn Cautious
Via The Motley Fool · October 21, 2025
IMF Sounds Alarm: Global Growth Slows, Developing Economies Face Mounting Debt Crisis
The International Monetary Fund (IMF) has issued a stark warning regarding the global economic outlook, projecting a deceleration in growth coupled with an alarming rise in debt risks for developing economies. This pronouncement, a consistent theme across its recent World Economic Outlook (WEO) and Fiscal Monitor reports, paints a challenging
Via MarketMinute · October 21, 2025
Johnson Y-Axis Adjustment(R) (\"Ring Dinger(R)\") Clarified as In-Scope Care Under Texas Law; Advanced Chiropractic Equipment LLC Addresses Confusion with Y-Strap Traction
Houston, Texas--(Newsfile Corp. - October 20, 2025) - Advanced Chiropractic Equipment LLC (ACE) and Your Houston Chiropractor, Gregory E. Johnson,...
Via Newsfile · October 20, 2025
The Industrial Giant's Resurgence: Why 3M (NYSE: MMM) Is Poised to Outperform the S&P 500 Over the Next Decade
After a decade of significant underperformance, marked by legal battles and strategic drift, industrial conglomerate 3M Company (NYSE: MMM) is now making aggressive moves to reclaim its former glory. MarketMinute predicts that this Dow Jones value stock, which has largely languished with minimal returns relative to the broader market over
Via MarketMinute · October 20, 2025
Q3 2025 Earnings Season: A High-Stakes Quarter for Market Direction
The stage is set, and the curtains are about to rise on the Q3 2025 earnings season, a period historically known to inject both volatility and direction into the financial markets. As investors brace for a deluge of corporate financial reports, the overarching sentiment is one of cautious optimism, albeit
Via MarketMinute · October 20, 2025
Global Trade Tensions: A Rollercoaster Ride for the Stock Market in October 2025
October 2025 has proven to be a turbulent month for global financial markets, as the persistent shadow of trade tensions and tariffs, particularly between the United States and China, continues to dictate investor sentiment and market volatility. While the month witnessed a dramatic escalation in rhetoric and retaliatory measures, a
Via MarketMinute · October 20, 2025
3 Dividend Stocks With 5% (or Higher) Yields to Buy Hand Over Fist in Octoberfool.com
These three stocks have elevated yields and attractive dividend histories.
Via The Motley Fool · October 20, 2025
2 Top Dividend Kings Every Income Investor Should Ownfool.com
These companies pay durable and steadily rising dividends.
Via The Motley Fool · October 20, 2025
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened interest is not merely an isolated phenomenon but rather a potent indicator of broader market movements, significantly impacting stock futures and the
Via MarketMinute · October 19, 2025
Global Economic Headwinds Intensify as China's Q3 GDP Forecast Signals Year-Low Growth, Sending Ripples Through International Markets
The global economy is bracing for a significant deceleration in 2025, a trend intensified by persistent trade tensions and widespread policy uncertainties. At the heart of this growing fragility lies China, the world's second-largest economy, whose third-quarter Gross Domestic Product (GDP) growth figures, expected to be unveiled tomorrow, October 20,
Via MarketMinute · October 19, 2025
Meet the 5%-Yielding Dividend Stock That Could Soar in 2026fool.com
Kenvue could start to recover in 2026.
Via The Motley Fool · October 19, 2025
Johnson & Johnson's M&A Strategy Is the Real Story for Investorsmarketbeat.com
Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.
Via MarketBeat · October 18, 2025
Why Kenvue Stock Tumbled by 13% on Thursdayfool.com
The company's baby powder product is under legal fire once again.
Via The Motley Fool · October 16, 2025